Mobile

A PHASE II, RANDOMIZED, PLACEBO-CONTROLLED, DOUBLE-BLIND STUDY OF THE SAFETY AND EFFICACY OF MPSK3169A IN PATIENTS WITH CORONARY HEART DISEASE OR HIGH RISK OF CORONARY HEART DISEASE

Mise à jour : Il y a 4 ans
Référence : EUCTR2012-000191-41

Femme et Homme

  • | Pays :
    • -
  • | Organes :
    • -
  • | Spécialités :
    • -

Extrait

• To evaluate the safety of MPSK3169A on top of standard-of-care (SOC) statin in patients with an low-density lipoprotein cholesterol (LDL-c) of 90−250 mg/dL and either coronary heart disease (CHD) or a CHD risk equivalent • To evaluate the ability of MPSK3169A to reduce LDL-c on top of SOC statin therapy in patients with an LDL-c of 90−250 mg/dL and either CHD or a CHD risk equivalent

Critère d'inclusion

  • Coronary Heart Disease or High Risk of Coronary Heart Disease

Liens